Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway

Reuters03-24

Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway

Alnylam entered a collaboration with Viz.ai to develop an AI-enabled care pathway intended to support earlier identification and referral for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).
The planned pathway combines the FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity and integration into clinical workflows.
The collaboration includes the AWARE study, a prospective implementation study evaluating AI-enabled screening in routine workflows and its impact on diagnostic timelines and care coordination.
The initiative is expected to launch at 5 pilot health systems later this year.
Alnylam is also supporting an American Heart Association-led, 3-year learning collaborative involving a 10-site cohort of multidisciplinary health systems focused on ATTR-CM care pathways.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621061321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621061321","market":"fut","top_or_hot":-1,"title":"Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alnylam entered a collaboration with Viz.ai to develop an AI-enabled care pathway intended to support earlier identification and referral for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).\n        </li>\n<li>\n          The planned pathway combines the FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity and integration into clinical workflows.\n        </li>\n<li>\n          The collaboration includes the AWARE study, a prospective implementation study evaluating AI-enabled screening in routine workflows and its impact on diagnostic timelines and care coordination.\n        </li>\n<li>\n          The initiative is expected to launch at 5 pilot health systems later this year.\n        </li>\n<li>\n          Alnylam is also supporting an American Heart Association-led, 3-year learning collaborative involving a 10-site cohort of multidisciplinary health systems focused on ATTR-CM care pathways.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alnylam entered a collaboration with Viz.ai to develop an AI-enabled care pathway intended to support earlier identification and referral for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).\n        </li>\n<li>\n          The planned pathway combines the FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity and integration into clinical workflows.\n        </li>\n<li>\n          The collaboration includes the AWARE study, a prospective implementation study evaluating AI-enabled screening in routine workflows and its impact on diagnostic timelines and care coordination.\n        </li>\n<li>\n          The initiative is expected to launch at 5 pilot health systems later this year.\n        </li>\n<li>\n          Alnylam is also supporting an American Heart Association-led, 3-year learning collaborative involving a 10-site cohort of multidisciplinary health systems focused on ATTR-CM care pathways.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6fvvWT:1","article_id":"2621061321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621061321","pubTimestamp":1774352123,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alnylam entered a collaboration with Viz.ai to develop an AI-enabled care pathway intended to support earlier identification and referral for patients with transthyretin-mediated amyloidosis cardiomyopathy .The planned pathway combines the FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity and integration into clinical workflows.The collaboration includes the AWARE study, a prospective implementation study evaluating AI-enabled screening in routine workflows and its impact on diagnostic timelines and care coordination.The initiative is expected to launch at 5 pilot health systems later this year.Alnylam is also supporting an American Heart Association-led, 3-year learning collaborative involving a 10-site cohort of multidisciplinary health systems focused on ATTR-CM care pathways.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ALNY":"阿尔尼拉姆制药公司","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4548":"巴美列捷福持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技"},"translate_title":"Alnylam与Viz.ai合作开发人工智能ATTR-CM检测和护理协调途径","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"Alnylam partners with Viz.ai on AI-enabled ATTR-CM detection and care coordination pathway\n    \n\n\n          Alnylam entered a collaboration with Viz.ai to develop an AI-enabled care pathway intended to support earlier identification and referral for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).\n        \n\n          The planned pathway combines the FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity and integration into clinical workflows.\n        \n\n          The collaboration includes the AWARE study, a prospective implementation study evaluating AI-enabled screening in routine workflows and its impact on diagnostic timelines and care coordination.\n        \n\n          The initiative is expected to launch at 5 pilot health systems later this year.\n        \n\n          Alnylam is also supporting an American Heart Association-led, 3-year learning collaborative involving a 10-site cohort of multidisciplinary health systems focused on ATTR-CM care pathways.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621061321","isCrawlerRequest":true}